A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Active, not recruiting · Phase 1 · NCT05512390
Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
At a glance
- Research payments reported, 2025
- $741,842
- U.S. investigators named
- 8
- Sites paid
- 16
- Planned or actual enrollment
- 39
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-319 (drug)
- Dates
- Started 2023-04-26; completion 2027-02
- Results posted
- Not yet
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), R/R follicular lymphoma (FL), or R/R CLL. Adverse events will be assessed. ABBV-319 is an investigational drug being developed for the treatment of R/R DLBCL, R/R FL, or R/R CLL. This study will …
From ClinicalTrials.gov, last updated 2026-08-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $741,842 in research payments for this study in 2025 (88 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Izidore Lossos, MD Hematology & Oncology · Miami, FL
- Abhijeet Kumar Hematology & Oncology · Baltimore, MD
- Fiona He, M.D. Hematology · Minneapolis, MN
- Alan P. Zausner Skarbnik, MD Hematology · Charlotte, NC
- Matthew A. Lunning, D.O. Medical Oncology · Omaha, NE
- Paola Ghione, MD Medical Oncology · Buffalo, NY
- Moshe Y. Levy, MD Medical Oncology · Dallas, TX
- Daruka Mahadevan, MD, PHD Medical Oncology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Texas Health Science Center at San Antonio $213,472
- Novant Health Clinical Research LLC $201,401
- The University of Arizona $75,736
- Abbott Northwestern Hospital, MN $45,034
- Alexian Brothers Health System $44,174
- Texas Oncology PA $37,908
- University of Miami Miller School of Medicine $37,201
- Memorial Sloan Kettering Cancer Center $31,088
- Memorial Sloankettering Cancer Center $27,565
- Ut MD Anderson Cancer Center $12,269
- Unehealth $8,441
- $3,024
- Texas Oncology Southwest Fort Worth $1,200
- Texas Oncology PA $1,200
- University of Miami $931
- Ut Health San Antonio $600
- North Campus Pharmacy Recieving $600
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.